Tris Pharma taps Anthony Amato to lead generics business development
Tris Pharma, a specialty pharmaceutical company, has a new executive. Anthony Amato has joined the company as executive vice president of business development for the company’s generics division.
"With our continued growth and evolution to a larger, more complex operation, one of our priorities has been to bring a seasoned pharmaceutical business development leader onto the Tris team. We are thrilled that Tony has joined Tris as our executive vice president, business development for our generics division." said Ketan Mehta Tris' founder and CEO. "Tony's extensive experience in growing specialty pharmaceutical businesses through complex transactions and global collaborations along with his goal-oriented leadership style are a natural fit for Tris' culture and strategic plan."
[Read more: Tris launches promethazine and codeine syrup]
"I am honored and excited by this opportunity to join Tris, engage with potential partners and investors and lead the business development efforts which will play a critical role in the future of Tris' Generic division." said Amato.
Amato’s expertise includes sourcing and executing valuable transactions, assessing market trends, cultivating successful partnerships, and training and overseeing global cross-functional teams. His 20+ years of business development experience includes leadership roles in companies such as Hudson Healthcare Partners, Alvogen, Lupin, Quadrant Capital Advisors, and Barr Laboratories.
[Read more: U.S. District Court upholds validity of Tris Pharma's Quillivant XR patents]
Amato holds an MBA in Finance and Accounting from Zicklin School of Business, Baruch College, City University of NY and Juris Doctor degree from Touro Law School.